

NEURON BIO

Neuron Bio specializes in the development of biosolutions for the pharmaceutical and agro-food industries via its divisions: BioPharma, Bioservices and Innofood by Neuron.

COMPANY PROFILE as at 11/30/14

Price	1,30
Price as at 07/01/2010	3,99
Equity Market Value	9.018.750,00 €
Nº of Shares	6.937.500
Max/Min	4,39/0,99



Volume	Shares	Turnover	Capital Increases
2014	15.626.000	36.094.000 €	2014 2.312.500 €
2013	1.008.000	1.722.000 €	2013 0 €
2012	367.000	1.147.000 €	2012 0 €
2011	615.000	1.452.000 €	2011 0 €
2010	1.539.000	5.963.000 €	2010 0 €

Ticker	NEU	Perc. of Equity Market Value in MAB	0,52%
Sector	Biotech / Pharma	Price Performance since 07/01/2010	-67,419


Price Performance per year (%)	2010	2011	2012	2013	2014
Neuron	-24,812	-30,000	14,286	-35,417	-16,129
MAB Index	-37,679	-6,312	2,293	183,437	-0,865
IBEX Small Cap Index	-18,316	-25,102	-24,448	44,290	-9,212
IBEX 35 Index	-17,428	-13,113	-4,655	21,417	8,612

MAJOR SHAREHOLDERS


Javier Tallada García de la Fuente	16,76%
Minority shareholders	83,24%




Sales Revenue




Ebitda



Net Income



Volume



NEURON BIO

Neuron Bio specializes in the development of biosolutions for the pharmaceutical and agro-food industries via its divisions: BioPharma, Bioservices and Innofood by Neuron.

INCOME (Annual)

	2011	2012	2013	Variation
Sales Revenue	418.316,00 €	200.261,00 €	53.073,00 €	-73%
Ebitda	-563.507,00 €	-774.034,00 €	-531.177,00 €	31%
Ebitda Margin	n.a.	n.a.	n.a.	
Net Income	-631.289,00 €	98.668,00 €	-1.138.865,00 €	-1254%
Net Margin	n.a.	49%	n.a.	

Performance Information	2011	2012	2013	*2014
ROE	N.A.	0,97%	N.A.	N.A.
ROA	N.A.	N.A.	N.A.	N.A.
Equity Market Value / Sales**	23,22	55,43	135,07	169,93
Equity Market Value / EBITDA	N.A.	N.A.	N.A.	N.A.
EPS	N.A.	0,02 €	N.A.	N.A.
PER	N.A.	112,50	N.A.	N.A.
Return Rate	N.A.	0,89%	N.A.	N.A.
Nº of Shares	4.625.000	4.625.000	4.625.000	6.937.500
Price as at 12-31	2,10	2,40	1,55	N.A.
Price				1,30





*2014 data is price / last public Financial Statements.

**Sales Revenue



There is no forecast from the Company

	2014E	2015E	2016E
Equity Market Value / Sales**	N.A.	N.A.	N.A.
Equity Market Value / EBITDA	N.A.	N.A.	N.A.
EPS	N.A.	N.A.	N.A.
PER	N.A.	N.A.	N.A.



Debt Analysis

	2011	2012	2013
Total debt/Ebitda	N.A.	N.A.	N.A.
Ebitda/Finance Costs	N.A.	N.A.	N.A.
Total debt/Equity	1,12	1,36	1,88